Myocardial Screening in Fetuses With Congenital Cytomegalovirus (CMV) Infection
Disorder of Cardiac Function
About this trial
This is an interventional diagnostic trial for Disorder of Cardiac Function focused on measuring cytomegalovirus, TORCH, prenatal diagnosis, congenital infections, fetal abnormalities, echocardiography, myocardial deformation
Eligibility Criteria
Inclusion Criteria:
- Patients referred because of suspected CMV IUI as demonstrated by seroconversion during pregnancy or during the 3 months that precede LMP or
- Patients referred because of suspected CMV IUI based on the presence borderline CMV serology
- US signs indicative of intrauterine CMV infection (CNS and non CNS involvement).
Exclusion Criteria:
- Multifetal pregnancy.
- Pregnant women planning to deliver elsewhere who are offered yet refuse to participate in the postnatal investigation following discharge from the hospital.
- Patients will be excluded if they had clinical heart failure, as defined by the New York Heart Association classification (NYHA, class II-IV) (Criteria committee of NYHA 1994), a history of cardiovascular disease or chronic renal insufficiency.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Pregnant women with CMV infection
Pregnant women with suspected CMV infection
An attempt to record the fetal myocardium will be done at the initial examination and at all the follow up examinations performed during pregnancy (every 3-4 weeks according to the clinical protocol currently in use at the OB-GYN US Unit). The participants will undergo a detailed fetal echocardiography according to standard guidelines (see below, section echocardiography).
The healthy women from the group will serve as controls. An attempt to record the fetal myocardium will be done at the initial examination and at all the follow up examinations performed during pregnancy (every 3-4 weeks according to the clinical protocol currently in use at the OB-GYN US Unit). The participants will undergo a detailed fetal echocardiography according to standard guidelines (see below, section echocardiography). As the control group-Newborns found to be negative for CMV will serve as control group.